2351 GMT - Alcidion's bull at Bell Potter thinks that the Australian medical-software provider is well placed to further extend its contract with Leidos's local subsidiary. Alcidion this week increased the total contract value of its agreement with Leidos to A$12.3 million and analyst Thomas Wakim is optimistic that this gets extended from 2028 through to 2036. Noting Alcidion's track record of low churn, he tells clients in a note that there is also potential for Leidos to take up additional modules over time. Bell Potter raises its target price 7.7% to A$0.14 and keeps a buy rating on the stock, which is up 4.6% at A$0.115. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
November 17, 2025 18:51 ET (23:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.